Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2012

01.01.2012 | Preclinical study

Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients

verfasst von: Nabila Chaher, Hugo Arias-Pulido, Nadija Terki, Clifford Qualls, Kamel Bouzid, Claire Verschraegen, Anne Marie Wallace, Melanie Royce

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory breast cancer (IBC) shows a high incidence in Tunisia and Egypt but epidemiological and molecular characteristics have not been described in Algeria. We compared 117 IBC and 59 non-IBC locally advanced breast cancers (LABC), for estrogen and progesterone receptors, HER2, and EGFR protein expression by immunohistochemistry, and HER2 gene amplification by chromogenic in situ hybridization. Demographic, clinico-pathological, and molecular variables were compared with chi-square and Fisher’s exact tests to test for significance (P < 0.05, two-tailed). Overall survival (OS) and disease-free survival (DFS) were plotted using Kaplan–Meier curves and compared using the log-rank test. Tumor emboli were detected in 77% of IBC. Palpable masses were found in all LABC but only in 32% of IBC (P < 0.001). Recurrences were higher in LABC than in IBC (48 vs. 35%; P = 0.14) but OS was worse in IBC (68 vs. 71%; P = 0.06). There were no significant differences between IBC and LABC by demographics or by clinico-pathological parameters. The majority of IBC and LABC tumors were luminal A (62 and 64%), followed by basal (~18%, each), triple negative (~18%, each), and HER2+ (~10%, each) subtypes. In multivariate analyses, grade was associated with worse OS (P = 0.04), and DFS (P < 0.001) in IBC; chemo- and radio-therapy were associated with improved OS and DFS, respectively (P < 0.05 for each) in LABC. In conclusion, IBC in Algeria shows similar characteristics to IBC described for Egypt and Tunisia with subtle molecular differences. Current therapeutic treatments were not very effective in this population and new approaches are much needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S et al (2010) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. doi:10.1093/annonc/mdq345 Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S et al (2010) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. doi:10.​1093/​annonc/​mdq345
2.
Zurück zum Zitat Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M (2009) Approach to inflammatory breast cancer. Can Fam Physician 55:25–31PubMed Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M (2009) Approach to inflammatory breast cancer. Can Fam Physician 55:25–31PubMed
3.
Zurück zum Zitat Singletary SE, Cristofanilli M (2008) Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 35:7–10PubMedCrossRef Singletary SE, Cristofanilli M (2008) Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 35:7–10PubMedCrossRef
4.
Zurück zum Zitat Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975PubMedCrossRef Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975PubMedCrossRef
5.
Zurück zum Zitat Boussen H, Bouzaiene H, Hassouna JB, Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal K et al (2010) Inflammatory breast cancer in Tunisia. Cancer 116:2730–2735PubMedCrossRef Boussen H, Bouzaiene H, Hassouna JB, Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal K et al (2010) Inflammatory breast cancer in Tunisia. Cancer 116:2730–2735PubMedCrossRef
6.
Zurück zum Zitat Soliman A, Banerjee M, Lo A, Ismail K, Hablas A, Seifeldin I, Ramadan M, Omar H, Fokuda A, Harford J et al (2009) High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt. Breast J 15:432–434PubMedCrossRef Soliman A, Banerjee M, Lo A, Ismail K, Hablas A, Seifeldin I, Ramadan M, Omar H, Fokuda A, Harford J et al (2009) High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt. Breast J 15:432–434PubMedCrossRef
7.
Zurück zum Zitat Mokhtar N, Elati J, Chabir R, Bour A, Elkari K, Schlossman NP, Caballero B, Aguenaou H (2001) Diet culture and obesity in Northern Africa. J Nutr 131:887S–892SPubMed Mokhtar N, Elati J, Chabir R, Bour A, Elkari K, Schlossman NP, Caballero B, Aguenaou H (2001) Diet culture and obesity in Northern Africa. J Nutr 131:887S–892SPubMed
8.
Zurück zum Zitat Labidi SI, Mrad K, Mezlini A, Ouarda MA, Combes JD, Abdallah MB, Romdhane KB, Viens P, Ayed FB (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19:473–480PubMedCrossRef Labidi SI, Mrad K, Mezlini A, Ouarda MA, Combes JD, Abdallah MB, Romdhane KB, Viens P, Ayed FB (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19:473–480PubMedCrossRef
9.
Zurück zum Zitat Dey S, Soliman A, Merajver S (2009) Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med Hypotheses 72:652–656PubMedCrossRef Dey S, Soliman A, Merajver S (2009) Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med Hypotheses 72:652–656PubMedCrossRef
10.
Zurück zum Zitat Lo AC, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Douglas JA, Alford SH, Merajver SD et al (2008) Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat 112:141–147PubMedCrossRef Lo AC, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Douglas JA, Alford SH, Merajver SD et al (2008) Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat 112:141–147PubMedCrossRef
11.
Zurück zum Zitat Duke T, Jahed N, Veneroso C, Da Roza R, Johnson O, Hoffman D, Barsky S, Levine P (2010) A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology. Oncol Rep 24:1277–1284PubMed Duke T, Jahed N, Veneroso C, Da Roza R, Johnson O, Hoffman D, Barsky S, Levine P (2010) A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology. Oncol Rep 24:1277–1284PubMed
12.
Zurück zum Zitat Levine PH, Young HA, Mark L, Rojowsky H, Holland JF, Pogo BG (2009) Increased detection of breast cancer virus sequences in inflammatory breast cancer. Adv Tumor Virol 1:3–7 Levine PH, Young HA, Mark L, Rojowsky H, Holland JF, Pogo BG (2009) Increased detection of breast cancer virus sequences in inflammatory breast cancer. Adv Tumor Virol 1:3–7
13.
Zurück zum Zitat Pogo B, Holland J, Levine P (2010) Human mammary tumor virus in inflammatory breast cancer. Cancer 116:2741–2744PubMedCrossRef Pogo B, Holland J, Levine P (2010) Human mammary tumor virus in inflammatory breast cancer. Cancer 116:2741–2744PubMedCrossRef
14.
Zurück zum Zitat Charafe-Jauffret E, Mrad K, Intidhar Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, Ginestier C, Esterni B, Birnbaum D, Ben Ayed F et al (2007) Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 16:352–358PubMedCrossRef Charafe-Jauffret E, Mrad K, Intidhar Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, Ginestier C, Esterni B, Birnbaum D, Ben Ayed F et al (2007) Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 16:352–358PubMedCrossRef
15.
Zurück zum Zitat Charafe-Jauffret E, Tarpin C, Bardou V, Bertucci F, Ginestier C, Braud A, Puig B, Geneix J, Hassoun J, Birnbaum D et al (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol 202:265–273PubMedCrossRef Charafe-Jauffret E, Tarpin C, Bardou V, Bertucci F, Ginestier C, Braud A, Puig B, Geneix J, Hassoun J, Birnbaum D et al (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol 202:265–273PubMedCrossRef
16.
Zurück zum Zitat Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D et al (2008) Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 8:28PubMedCrossRef Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D et al (2008) Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 8:28PubMedCrossRef
17.
Zurück zum Zitat Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C et al (2002) Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161:1223–1233PubMedCrossRef Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C et al (2002) Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161:1223–1233PubMedCrossRef
18.
Zurück zum Zitat Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Merajver S, Kleer C, Harris A, Van Marck E, Dirix L et al (2004) Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85:13–22PubMedCrossRef Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Merajver S, Kleer C, Harris A, Van Marck E, Dirix L et al (2004) Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85:13–22PubMedCrossRef
19.
Zurück zum Zitat Mourali N, Muenz L, Tabbane F, Belhassen S, Bahi J, Levine P (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46:2741–2746PubMedCrossRef Mourali N, Muenz L, Tabbane F, Belhassen S, Bahi J, Levine P (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46:2741–2746PubMedCrossRef
20.
Zurück zum Zitat NCI/NHLBI OEITFM Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: NHLBI 1998 NCI/NHLBI OEITFM Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: NHLBI 1998
21.
Zurück zum Zitat Arias-Pulido H, Smith H, Joste N, Bocklage T, Qualls C, Chavez A, Prossnitz E, Verschraegen C (2009) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 114:480–485PubMedCrossRef Arias-Pulido H, Smith H, Joste N, Bocklage T, Qualls C, Chavez A, Prossnitz E, Verschraegen C (2009) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 114:480–485PubMedCrossRef
22.
Zurück zum Zitat Lachin J (2000) Biostatistical methods. Wiley, New York, pp 272–285CrossRef Lachin J (2000) Biostatistical methods. Wiley, New York, pp 272–285CrossRef
23.
Zurück zum Zitat Lê MG, Arriagada R, Bahi J, Pfeiffer F, Cammoun M, Tabbane F, Rubino C (2006) Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? The Breast 15:355–362PubMedCrossRef Lê MG, Arriagada R, Bahi J, Pfeiffer F, Cammoun M, Tabbane F, Rubino C (2006) Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? The Breast 15:355–362PubMedCrossRef
24.
Zurück zum Zitat Lo A, Georgopoulos A, Kleer C, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar H, Douglas J et al (2009) Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 18:55–59PubMedCrossRef Lo A, Georgopoulos A, Kleer C, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar H, Douglas J et al (2009) Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 18:55–59PubMedCrossRef
25.
Zurück zum Zitat Chang S, Alderfer J, Asmar L, Buzdar A (2000) Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64:157–163PubMedCrossRef Chang S, Alderfer J, Asmar L, Buzdar A (2000) Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64:157–163PubMedCrossRef
26.
Zurück zum Zitat Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH (2001) Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 7:398–404PubMedCrossRef Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH (2001) Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 7:398–404PubMedCrossRef
27.
Zurück zum Zitat Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol 16:3731–3735PubMed Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol 16:3731–3735PubMed
28.
Zurück zum Zitat Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351–375PubMedCrossRef Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351–375PubMedCrossRef
29.
Zurück zum Zitat Dey S, Soliman A, Hablas A, Seifeldein I, Ismail K, Ramadan M, El-Hamzawy H, Wilson M, Banerjee M, Boffetta P et al (2010) Urban–rural differences in breast cancer incidence in Egypt (1999–2006). Breast 16:417–423CrossRef Dey S, Soliman A, Hablas A, Seifeldein I, Ismail K, Ramadan M, El-Hamzawy H, Wilson M, Banerjee M, Boffetta P et al (2010) Urban–rural differences in breast cancer incidence in Egypt (1999–2006). Breast 16:417–423CrossRef
30.
Zurück zum Zitat Gruber G, Ciriolo M, Altermatt H, Aebi S, Berclaz G, Greiner R (2004) Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 109:144–148PubMedCrossRef Gruber G, Ciriolo M, Altermatt H, Aebi S, Berclaz G, Greiner R (2004) Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 109:144–148PubMedCrossRef
31.
Zurück zum Zitat Le M, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli J et al (2005) Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 6:439–445PubMedCrossRef Le M, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli J et al (2005) Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 6:439–445PubMedCrossRef
32.
Zurück zum Zitat Dawood S, Ueno N, Cristofanilli M (2008) The medical treatment of inflammatory breast cancer. Semin Oncol 35:64–71PubMedCrossRef Dawood S, Ueno N, Cristofanilli M (2008) The medical treatment of inflammatory breast cancer. Semin Oncol 35:64–71PubMedCrossRef
33.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384PubMedCrossRef Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384PubMedCrossRef
34.
Zurück zum Zitat Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066–1072PubMedCrossRef Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066–1072PubMedCrossRef
35.
Zurück zum Zitat Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10:581–588PubMedCrossRef Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10:581–588PubMedCrossRef
36.
Zurück zum Zitat Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N (2010) Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248–3255PubMedCrossRef Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N (2010) Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248–3255PubMedCrossRef
Metadaten
Titel
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients
verfasst von
Nabila Chaher
Hugo Arias-Pulido
Nadija Terki
Clifford Qualls
Kamel Bouzid
Claire Verschraegen
Anne Marie Wallace
Melanie Royce
Publikationsdatum
01.01.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1422-5

Weitere Artikel der Ausgabe 2/2012

Breast Cancer Research and Treatment 2/2012 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.